Psoriasis Clinical Trials in Atlanta
View 24 new treatments for Psoriasis in Atlanta, GA, and other areas near me, such as Sandy Springs. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.TAK-279 for Plaque Psoriasis
Takeda Clinic, Atlanta + 3 more
This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.Show More
Verified
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Atlanta + 4 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Subcutaneous Risankizumab for Psoriasis
AbbVie Clinic, Alpharetta + 1 more
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Atlanta + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
No Placebo Trial
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Decatur + 1 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Atlanta + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Deucravacitinib for Psoriatic Arthritis
Bristol-Myers Squibb Clinic, Gainesville + 1 more
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.Show More
Tildrakizumab SC Injection for Psoriatic Arthritis
Sun Clinic, Decatur + 1 more
An open label phase 3 study
No Placebo Trial
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Atlanta + 1 more
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Douglasville + 1 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Frequently Asked Questions
How much do psoriasis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do psoriasis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in Atlanta, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
What promising new drugs are being tested?
In Atlanta, psoriasis research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Guselkumab, Risankizumab, and Deucravacitinib.